A new target for proteasome inhibitors: FoxM1

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• The proteasome degrades cellular proteins, and inhibitors are used in cancer therapy.
• Proteasome inhibitors selectively kill cancer cells, but their mechanisms are not fully understood.
• Forkhead Box M1 (FoxM1) is an oncogenic transcription factor overexpressed in many cancers, driving tumor progression.

Purpose of the Study:

• To review novel mechanisms of proteasome inhibitors.
• To discuss new thiazole antibiotic proteasome inhibitors.
• To explore the role of FoxM1 inhibition in proteasome inhibitor anticancer activity.

Main Methods:

• Literature review of recent publications on proteasome inhibitors and FoxM1.
• Cell-based screening to identify thiazole antibiotics (siomycin A, thiostrepton) as FoxM1 inhibitors.
• Analysis of known proteasome inhibitors (MG115, MG132, bortezomib) for FoxM1 activity.

Main Results:

• Proteasome inhibitors suppress FoxM1 expression and induce apoptosis in human tumor cell lines.
• Thiazole antibiotics siomycin A and thiostrepton inhibit FoxM1 activity and expression.
• Known proteasome inhibitors also inhibit FoxM1 transcriptional activity and expression.

Conclusions:

• Negative regulation of FoxM1 by proteasome inhibitors correlates with apoptosis induction.
• FoxM1 suppression may be a universal mechanism contributing to the anticancer activity of proteasome inhibitors.
• Further research is needed to determine the significance of FoxM1 suppression in proteasome inhibitor-induced apoptosis and anticancer efficacy.